Davids Maris

Specialty biopharma Emergent Biosolutions Inc (NYSE: EBS) has seen its stock rise more than 40 percent over the past two years, and investors shouldn't expect to see such outsized returns going forward, according to Wells Fargo.  The Analyst Wells Fargo's David Maris downgraded...